GVK BIO signs agreement to acquire Vanta Bioscience
Facility houses GLP-trained scientific personnel with expertise in study design and execution of regulatory directed studies leading to IND filings
GVK BIO, Asia’s leading drug R&D organisation, has signed a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organisation operating out of Chennai, India.
Complying with OECD GLP, ISO, US FDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines, Vanta Bioscience offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries.
The state-of-the-art facility is GLP and AAALAC accredited, benefits from high-end equipment, and has individually ventilated cages and Intelligent Building Management systems. The facility houses GLP-trained scientific personnel with experience and expertise in study design and execution of regulatory directed studies leading to IND (investigational new drug) filings.
'The acquisition is in line with our business strategy of being an integrated drug discovery services provider. We are constantly investing in upgrading our capabilities to provide world class R&D services,' said Manni Kantipudi, CEO of GVK BIO. 'Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology.'
GVK Biosciences provides a broad spectrum of integrated services across the R&D and manufacturing value chain, with a focus on speed and quality. GVK BIO capabilities include discovery services, contract manufacturing, formulations, informatics and clinical development.
